Siren L.L.C. Has $14.95 Million Stock Holdings in Stoke Therapeutics, Inc. $STOK

Key Points

• Siren L.L.C. has increased its stake in Stoke Therapeutics by 12.4%, owning 2,247,347 shares valued at approximately $14.9 million, making it the 28th largest holding in its portfolio.
• Analysts generally maintain a positive outlook on Stoke Therapeutics, with a consensus rating of "Buy" and a target price averaging $25.57.
• Stoke Therapeutics reported earnings of ($0.40) per share for the last quarter, beating expectations, but its revenue of $13.82 million fell short of the consensus estimate of $31.51 million.

Siren L.L.C. increased its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 12.4% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,247,347 shares of the company's stock after purchasing an additional 247,347 shares during the quarter. Stoke Therapeutics accounts for 0.9% of Siren L.L.C.'s holdings, making the stock its 28th biggest position. Siren L.L.C. owned approximately 4.12% of Stoke Therapeutics worth $14,945,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. AlphaQuest LLC bought a new stake in Stoke Therapeutics during the 1st quarter worth approximately $72,000. Erste Asset Management GmbH bought a new stake in Stoke Therapeutics during the 1st quarter worth approximately $2,670,000. Wellington Management Group LLP increased its stake in Stoke Therapeutics by 0.9% during the 1st quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock worth $904,000 after purchasing an additional 1,148 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in Stoke Therapeutics during the 1st quarter worth approximately $92,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Stoke Therapeutics during the 1st quarter worth approximately $107,000.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 4,504 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $12.82, for a total transaction of $57,741.28. Following the completion of the sale, the insider owned 16,775 shares of the company's stock, valued at $215,055.50. This trade represents a 21.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Jonathan Allan sold 13,712 shares of the firm's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $15.00, for a total value of $205,680.00. Following the sale, the general counsel directly owned 19,631 shares of the company's stock, valued at $294,465. This represents a 41.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,432 shares of company stock valued at $345,775 in the last ninety days. Insiders own 9.50% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on STOK. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Wedbush raised their price target on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. HC Wainwright decreased their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $25.57.

Stoke Therapeutics Stock Down 0.1%

Shares of NASDAQ STOK traded down $0.01 during trading hours on Friday, hitting $19.76. The company had a trading volume of 623,532 shares, compared to its average volume of 934,902. The stock has a market capitalization of $1.08 billion, a P/E ratio of 23.25 and a beta of 1.14. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $20.00. The firm's 50 day moving average is $14.09 and its 200-day moving average is $10.71.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. The company had revenue of $13.82 million during the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. On average, sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.